IP Library Granted Patent US 10,435,441
Granted Patent B2
US 10,435,441 · App. 15/274,357 · Granted Oct 8, 2019

HTT repressors and uses thereof

Inventors: Steven Froelich (Richmond, CA); Jeffrey C. Miller (Richmond, CA); David Paschon (Richmond, CA); Edward J. Rebar (Richmond, CA); Bryan Zeitler (Richmond, CA); H. Steve Zhang (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C07K14/47A61K48/0075C07K14/4702C07K14/4703C07K2319/81C12N15/8645
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,435,441
App. No.
15/274,357
Granted
Oct 8, 2019
Kind
B2
Abstract

Disclosed herein are Htt repressors and methods and compositions for use of these Htt repressors.

Claims (19)

1. A non-naturally occurring zinc finger protein transcription factor (ZFP-TF) that represses expression of mutant human or mouse Htt gene (mHtt), the zinc finger protein transcription factor comprising:

(a) a transcriptional repression domain; and

(b) a zinc finger protein designated SBS#45643 or SBS#46025, the zinc finger protein comprising 5 zinc finger domains ordered F1 to F5 as follows:

(i) F1: QSGDLTR (SEQ ID NO:1);

F2: QSGDLTR (SEQ ID NO:1);

F3: QSGDLTR (SEQ ID NO:1);

F4: KHGNLSE (SEQ ID NO:2); and

F5: KRCNLRC (SEQ ID NO:3); or

(ii) F1: CPSHLTR (SEQ ID NO:4);

F2: QSGDLTR (SEQ ID NO:1);

F3: KHGNLSE (SEQ ID NO:2);

F4: KRCNLRC (SEQ ID NO:3); and

F5: RQFNRHQ (SEQ ID NO:5).

2. A polynucleotide encoding one or more zinc finger protein transcription factors of claim 1 .

3. An AAV vector comprising the polynucleotide of claim 2 .

4. A host cell comprising one or more zinc finger protein transcription factors of claim 1 .

5. A pharmaceutical composition comprising one or more AAV vectors according to claim 3 .

6. A method of repressing expression of a mutant Htt gene in a neuronal cell in a brain, the method comprising intrastriatally administering to the cell one or more polynucleotides according to claim 2 .

7. A method of treating and/or preventing Huntington's Disease in a subject in need thereof, the method comprising administering one or more AAV vectors according to claim 3 into the striatum of the subject in need thereof.

Assignments (2)
CHANGE OF NAME Recorded Mar 9, 2018
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 045545/0952 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2016
From: FROELICH, STEVEN; MILLER, JEFFREY C.; PASCHON, DAVID; REBAR, EDWARD J.; ZEITLER, BRYAN; ZHANG, H. STEVE
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 040788/0443 →
Continuity (2)
Provisional Application 62222588 · Sep 23, 2015
Related Publication 20170096460A1 · Apr 6, 2017
Cited By (1)
US 12,551,575